
This phase 2b trial assessed the efficacy and safety of denifanstat, a fatty acid synthase inhibitor, in treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. Among 168 participants, denifanstat significantly improved liver histology and MASH resolution compared to placebo, with manageable side effects. The findings support further development of denifanstat in phase 3 trials as a potential therapeutic option for MASH-related liver fibrosis.
Like
Save
Share